Workflow
恒瑞医药:HRS-2162注射液获药物临床试验批准通知书

Core Viewpoint - Heng Rui Medicine (600276) has received approval from the National Medical Products Administration for clinical trials of HRS-2162 injection, a new generation muscle relaxant antagonist, which is expected to be the first of its kind in the market [1] Company Summary - The company’s subsidiary, Fujian Shengdi Pharmaceutical Co., Ltd., will soon initiate clinical trials for HRS-2162 injection [1] - HRS-2162 injection is designed to counteract the pharmacological effects of muscle relaxants and rapidly restore muscle tone [1] - The total research and development investment for the HRS-2162 injection project has reached approximately 28.25 million yuan [1] Industry Summary - Currently, there are no similar products approved for market release domestically or internationally, indicating a potential market opportunity for HRS-2162 injection [1]